On October 22, U.S. spot Solana (SOL) exchange-traded funds experienced net outflows totaling $8.9 million, reversing a $0.6 million inflow from the previous day. The Bitwise Solana Staking ETF (BSOL) led with $5.7 million in outflows, followed by Grayscale Solana Trust (GSOL) with $3.2 million. The other five Solana ETFs showed no net flows, and no fund recorded inflows that day. Over the past five trading sessions through October 22, combined net outflows reached $30.3 million, though since their launch, these funds have accumulated $1.532 billion in net inflows overall. This trend highlights some short-term investor caution despite long-term interest in Solana-based ETFs.
The U.S. spot Solana ETFs net outflow of $8.9 million on October 22 provides context for cryptocurrency market activity. For readers following major cryptocurrencies on Pluang, as of Oct 24, 2026 00:22 WIB, 44 of 50 priced cryptos rose while 5 fell. Among notable movers, COTI gained 6.62% with a typical hold time of 122 days and a strong 84% sell order activity, contrasting with BCH's 5.09% rise and 56% sell activity, and VET's 4.97% increase paired with an 88% sell order share.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
